

Examination on the merits and allowance of the pending claims is earnestly  
requested.




22504

PATENT TRADEMARK OFFICE

Respectfully submitted,

Bin Wu et al.

Davis Wright Tremaine LLP

  
\_\_\_\_\_  
Jane E. R. Potter  
Registration No. 33,332

Version with marking to show changes made

Claim 2 is cancelled.

1. (Amended) An isolated KIAA0175 inhibitor wherein said KIAA0175 inhibitor is [selected from the group consisting of] an anti-sense molecule [, a ribozyme, an antibody, an antibody fragment, a protein, a polypeptide and a small molecule].

3. (Amended) The isolated KIAA0175 inhibitor of claim [2] 1 wherein said anti-sense molecule or the complement thereof comprises at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

5. (Amended) The isolated KIAA0175 inhibitor of claim 2 wherein said anti-sense molecule comprises a nucleic acid sequence [selected from the group consisting] of SEQ ID NO:1[, SEQ ID NO:3 and SEQ ID NO:5].

20. (Amended) A composition, comprising a therapeutically effective amount of at least one KIAA0175 inhibitor in a pharmaceutically acceptable carrier wherein at least one of said KIAA0175 inhibitors is an antisense molecule.

25. (Amended) The composition of claim 22 wherein said anti-sense molecule comprises a nucleic acid sequence [selected from the group consisting] of SEQ ID NO:1, [SEQ ID NO:3 and SEQ ID NO:5].